Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameJXR
Stock Code01951
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities中美領先的輔助生殖服務供應商,主要提供輔助生殖服務、管理服務及輔助醫療服務。擁有及經營成都西囡婦科醫院及深圳中山泌尿外科醫院,共同管理錦江生殖中心,並管理美國HRC Medical。
Listing Date2019-06-25
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國四川省成都市錦江區靜沙北路301號
Business Address (Hong Kong)香港銅鑼灣勿地臣街1號時代廣場二座31樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.jxr-fertility.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 8.54 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 1e-05 / shares
Offer Period2019-06-13 to 2019-06-18
Global Offering Shares357,124,000 shares
HK Public Offer Shares (Initial)35,716,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)321,408,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO2,380,815,802 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share38.5%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 3,049,838,960

Stock Connect Inclusion Analysis

HK Market Cap HK$ 5.99B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣212.1百萬元
Period-End Cash Balance人民幣1,184.2百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2016
Revenue 56,595
Cost of sales -40,378
Gross profit 16,217
Other income and gains, net 4
Administrative expenses -3,379
Operating profit 12,842
Net finance costs -75
Profit before tax 12,767
Income tax expense 0
Profit for the year 12,767
Balance Sheet
Item 20162017-07
Cash and cash equivalents 4,835
Trade and bills receivables 7,063
Total current assets 11,898
Total current liabilities 7,994
Total equity 4,238
Interest-bearing borrowings 1,8060
Cash Flow Statement
Item 20162017-07
Net cash from operating activities 21,134
Net cash from investing activities -812
Net cash from financing activities -21,155
Net increase in cash -833
Depreciation of PP&E 334256
Purchase of PP&E -816-619
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 9.28
First Day OpenHK$ 9.9
First Day Change8.67%
First Day Volume228624000.0
First Day Turnover2239680000.0
Use of Proceeds
1、約25.0%或702.0百萬港元將用于拓展及升級我們中國網絡的現有輔助生殖醫療機構及招聘醫療專業人士; 2、約20.0%或561.6百萬港元將用于我們目前并無經營的中國省份的額外輔助生殖醫療機構潛在收購; 3、約10.0%或280.8百萬港元將用于投資研發以改善整體表現及維持我們ART的前沿地位; 4、約20.0%或561.6百萬港元將用于輔助生殖服務服務鏈的輔助生殖服務提供商及業務潛在收購; 5、約15.0%或421.2百萬港元將用于改善品牌專注度以及中國及美國對輔助生殖服務的整體專注; 6、約10.0%或280.8百萬港元將用于營運資金及一般企業用途。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 中信证券(香港)有限公司 CE AAK249
Overall Coordinators (4)
Morgan Stanley Asia Limited CE AAD291 中信里昂证券有限公司 CE AAB893 Citigroup Global Markets Asia Limited CE AAA137 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Bookrunners (10)
Morgan Stanley Asia Limited CE AAD291 中信里昂证券有限公司 CE AAB893 Citigroup Global Markets Asia Limited CE AAA137 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 招银国际融资有限公司 CE AVM940 中信建投(国际)融资有限公司 CE BAU112 农银国际融资有限公司 CE AWL249 ICBC INTERNATIONAL CAPITAL LIMITED CE AQW615 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 Mirae Asset Securities (HK) Limited CE BJB333
Joint Lead Managers (10)
Morgan Stanley Asia Limited CE AAD291 中信里昂证券有限公司 CE AAB893 Citigroup Global Markets Asia Limited CE AAA137 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 招银国际融资有限公司 CE AVM940 中信建投(国际)融资有限公司 CE BAU112 农银国际融资有限公司 CE AWL249 ICBC INTERNATIONAL CAPITAL LIMITED CE AQW615 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 Mirae Asset Securities (HK) Limited CE BJB333

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Ally Bridge LB Healthcare Master Fund Limited 235,174,520 HKD — 7.71% — 6 months 2019-12-25
2 Cormorant Asset Management, LP 156,777,320 HKD — 5.14% — 6 months 2019-12-25
3 Hillhouse Funds 548,746,240 HKD — 17.99% — 6 months 2019-12-25
4 Worldwide Healthcare Trust PLC 235,174,520 HKD — 7.71% — 6 months 2019-12-25

Directors & Management

PositionChinese nameEnglish Name
Chairman王彬—
Company Secretary劉竑琨—
No director data available.

Major Shareholders

Major Shareholders & HoldingsJinxin Fertility BVI持股21.10%,Amethyst Gem持股18.77%,HRC Investment持股15.15%,Jinxin Global BVI持股5.50%。
About this page

This page shows JXR (01951) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect